CDT Equity Inc. (NASDAQ:CDT) Sees Large Increase in Short Interest

Posted by Geri Gentry on Sep 26th, 2026

CDT Equity Inc. (NASDAQ:CDT – Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 239,903 shares, an increase of 467.9% from the August 31st total of 42,243 shares. Currently, 32.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 6,870,827 shares, the short-interest ratio is presently 0.0 days.

Analysts Set New Price Targets

A number of research firms have commented on CDT. Wall Street Zen upgraded CDT Equity from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a report on Monday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Read Our Latest Report on CDT

CDT Equity Price Performance

Shares of CDT stock traded down $0.04 on Friday, hitting $0.08. 25,908,804 shares of the company’s stock were exchanged, compared to its average volume of 6,776,378. The company has a 50 day moving average of $1.93 and a 200 day moving average of $24.26. The stock has a market cap of $63,200.00, a P/E ratio of -0.00 and a beta of 1.48. CDT Equity has a 12 month low of $0.08 and a 12 month high of $1,778.00.

Shares of CDT Equity are scheduled to reverse split on the morning of Tuesday, September 29th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, September 28th.

CDT Equity (NASDAQ:CDT – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($8.71) EPS for the quarter.

About CDT Equity

(Get Free Report)

CDT Equity, Inc, traded on the Nasdaq under the symbol CDT, is associated with Conduit Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune and inflammatory diseases.

The company’s business model centers on acquiring and advancing clinical-stage drug candidates through partnerships with academic institutions and pharmaceutical companies. Its portfolio has included investigational therapies intended to address conditions such as systemic sclerosis and other immune-mediated diseases, although the status and composition of its development programs may change as clinical and corporate activities progress.

Conduit Pharmaceuticals was established to help translate externally developed drug candidates into commercial medicines.